# Longevity & Aging Biotech Companies Landscape

> Last updated: February 2025
> Scope: Comprehensive profiles of companies working on aging biology, cellular reprogramming, senolytics, diagnostics, and AI-driven longevity research.

---

## Table of Contents

1. [Cellular Reprogramming & Rejuvenation](#1-cellular-reprogramming--rejuvenation)
2. [Senescence-Targeting Therapeutics](#2-senescence-targeting-therapeutics)
3. [Multi-Pipeline & Platform Companies](#3-multi-pipeline--platform-companies)
4. [Gene Therapy for Aging](#4-gene-therapy-for-aging)
5. [Mitochondrial & Metabolic Targets](#5-mitochondrial--metabolic-targets)
6. [Plasma-Based Therapies](#6-plasma-based-therapies)
7. [AI-Driven Drug Discovery & Aging Clocks](#7-ai-driven-drug-discovery--aging-clocks)
8. [Diagnostics & Biomarker Companies](#8-diagnostics--biomarker-companies)
9. [Veterinary Longevity](#9-veterinary-longevity)
10. [Summary Table](#10-summary-table)

---

## 1. Cellular Reprogramming & Rejuvenation

### 1.1 Altos Labs

| Field | Details |
|-------|---------|
| **Founded** | 2022 |
| **Headquarters** | San Francisco, CA / Cambridge, UK / Japan |
| **Funding** | $3 billion initial funding -- the most heavily funded biotech startup in history |
| **Key Investors** | Jeff Bezos, Yuri Milner, ARCH Venture Partners |
| **Employees** | 300+ scientists across three institutes |

**Technology & Focus:**
Altos Labs is focused on cellular reprogramming and rejuvenation biology, investigating how to reverse the aging process at the cellular level. Their core approach leverages Yamanaka factor-based partial reprogramming to restore youthful gene expression patterns without inducing full dedifferentiation (which would risk teratoma formation).

**Pipeline & Milestones:**
- Began early human safety testing in **August 2025**, representing a landmark moment for the reprogramming field's transition from bench to bedside.
- Preclinical programs across multiple tissue types and organ systems.
- Extensive basic research into the mechanisms of cellular aging and rejuvenation.

**Key Personnel:**
- **Juan Carlos Izpisua Belmonte** -- Scientific Advisor; pioneer in partial reprogramming research; demonstrated that cyclic expression of Yamanaka factors could reverse age-related hallmarks in mice without causing tumors.

**Partnerships & Collaborations:**
- Broad academic collaborations with top-tier universities and research institutes.
- Operates three global research institutes to attract world-class talent.

**Assessment:**
With $3B in initial funding, Altos Labs has unparalleled resources in the longevity space. Their move into human safety testing in 2025 is a critical proof point. However, the company has been relatively secretive about specific data outputs.

---

### 1.2 Calico Life Sciences (Alphabet/Google)

| Field | Details |
|-------|---------|
| **Founded** | 2013 |
| **Headquarters** | South San Francisco, CA |
| **Parent Company** | Alphabet Inc. (Google) |
| **Leadership** | Art Levinson (Chairman), Hal Barron (previous CEO) |

**Technology & Focus:**
Calico takes a broad approach to understanding the biology of lifespan and developing interventions for age-related diseases. Their research spans genetics of aging, computational biology, and drug development.

**Pipeline & Key Programs:**
- Drug development programs targeting age-related diseases (specifics are not widely disclosed).
- Deep investment in understanding fundamental biology of aging using model organisms (notably naked mole rats, long-lived species studies).
- Relatively secretive about specific pipeline progress.

**Partnerships:**
- **AbbVie Collaboration:** Multi-year partnership valued at over **$1.5 billion**, focused on developing and commercializing therapies for age-related diseases including neurodegeneration and cancer. One of the largest pharma-longevity collaborations to date.

**Data Releases:**
- Published research on aging genetics and computational biology.
- Notable publications on long-lived species genomics.
- Limited disclosure on drug development progress.

**Assessment:**
Backed by Alphabet's resources and the AbbVie partnership, Calico has deep pockets and long time horizons. However, their secretive nature makes external assessment difficult. Over a decade in, the lack of visible clinical-stage assets has drawn criticism from some in the field.

---

### 1.3 Retro Biosciences

| Field | Details |
|-------|---------|
| **Founded** | 2021 |
| **Headquarters** | Redwood City, CA |
| **Funding** | $180M seed (led by Sam Altman); raising $1B Series A at $5B valuation (Jan 2025); chasing $5B valuation (Dec 2025) |
| **Key Backer** | Sam Altman (OpenAI CEO) |

**Technology & Focus:**
Retro pursues three parallel approaches to extend healthy human lifespan by 10 years:
1. **Cellular Reprogramming** -- partial reprogramming to rejuvenate aged cells.
2. **Autophagy Enhancement** -- boosting the cell's waste-clearing machinery.
3. **Plasma Therapeutics** -- leveraging insights from parabiosis research.

**Pipeline & Milestones:**
- **First human trial** planned in Australia by end of 2025.
- Multi-pronged strategy provides diversification across mechanisms of action.

**Funding Trajectory:**
- $180M seed round was among the largest in longevity biotech history.
- Rapid progression to a potential $5B valuation within ~3 years of founding.

**Assessment:**
Retro's ambitious three-pronged approach and substantial funding position it as one of the most aggressive entrants in the longevity space. The planned Australian human trial in 2025 will be a key inflection point.

---

### 1.4 NewLimit

| Field | Details |
|-------|---------|
| **Founded** | December 2021 |
| **Funding** | $105M initial investment |
| **Founders** | Brian Armstrong (Coinbase co-founder), Blake Byers |

**Technology & Focus:**
NewLimit focuses on **epigenetic reprogramming** -- the targeted reversal of age-related epigenetic changes without full cellular reprogramming. The premise is that aging is largely an epigenetic phenomenon and can be reversed by restoring youthful methylation patterns.

**Pipeline:**
- Developing epigenetic reprogramming therapies for age-related diseases.
- Specific pipeline candidates and clinical timelines not publicly disclosed as of early 2025.

**Assessment:**
With strong tech-sector backing and $105M in initial funding, NewLimit represents the growing interest from Silicon Valley founders in longevity biotech. Their epigenetic focus is scientifically grounded in mounting evidence that epigenetic drift is a primary driver of aging.

---

### 1.5 Turn Biotechnologies

| Field | Details |
|-------|---------|
| **Technology Platform** | ERA (Epigenetic Reprogramming of Aging) -- mRNA-based |
| **Lead Candidate** | TRN-001 (IND-enabling studies; targeting clinical trial 2026) |
| **Delivery Platforms** | eTurna lipid platform; acquired ARMMs vesicular technology (March 2025) |

**Pipeline & Milestones:**
- **TRN-001**: In IND-enabling studies as of 2025, targeting clinical trial initiation in **2026**.
- **FDA Engagement**: Received positive feedback from FDA in **October 2023**, supporting the development path.
- **Skin Rejuvenation**: Demonstrated reversal of hallmarks of aging in human skin tissue.

**Partnerships:**
- **HanAll Biopharma**: Deal valued at up to **$300M**, covering ophthalmology and otology applications of ERA platform technology.

**Delivery Technology:**
- **eTurna**: Proprietary lipid nanoparticle platform for mRNA delivery.
- **ARMMs**: Acquired vesicular technology (March 2025) to expand delivery capabilities beyond lipid nanoparticles.

**Recent Developments:**
- **October 2025**: Klotho Neurosciences signed a Letter of Intent (LOI) to acquire Turn Bio assets, but the LOI expired without completion. Status of Turn Bio's independent operations remains to be clarified.

**Assessment:**
Turn Bio's mRNA-based approach to epigenetic reprogramming is distinctive and leverages proven mRNA delivery technology. The HanAll partnership validates the commercial potential, though the expired Klotho LOI raises questions about the company's trajectory.

---

### 1.6 Life Biosciences

| Field | Details |
|-------|---------|
| **Technology** | Epigenetic reprogramming (partial reprogramming for therapeutic applications) |
| **Pipeline** | Expected human clinical trials in early **2026** (eye application) |

**Technology & Focus:**
Life Biosciences has harnessed partial reprogramming for therapeutic use, developing approaches to reverse age-related cellular damage in specific tissues.

**Pipeline:**
- Lead program targets ophthalmic indications, with human clinical trials anticipated in early 2026.
- The eye is considered an attractive first target for reprogramming therapies due to its immune-privileged status and accessibility for local delivery.

**Assessment:**
Life Biosciences' focus on ocular applications provides a pragmatic entry point for reprogramming technology, following a tissue-specific strategy that may de-risk the approach compared to systemic delivery.

---

## 2. Senescence-Targeting Therapeutics

### 2.1 Unity Biotechnology

| Field | Details |
|-------|---------|
| **Technology** | Senolytic therapies (clearing senescent cells) |
| **Lead Candidate** | UBX1325 (BCL-xL inhibitor, intravitreal injection) |
| **Target Indication** | Diabetic Macular Edema (DME) |
| **Funding** | $55M Series C led by Foresite Capital (2024) |

**Pipeline & Clinical Data:**
- **UBX1325** for DME:
  - **ASPIRE Trial (Phase 2b)**: Demonstrated **5.6 letters improvement** in best-corrected visual acuity at 48 weeks.
  - Results published in **NEJM Evidence** -- a significant validation for the senolytic field.
  - Intravitreal delivery allows direct targeting of senescent cells in the retina.

**Assessment:**
Unity's ASPIRE data represent one of the strongest clinical proof points for senolytic therapy to date. Publication in NEJM Evidence elevates the credibility of the senescence-clearing approach. The 2024 Series C positions the company for continued development.

---

### 2.2 Rubedo Life Sciences

| Field | Details |
|-------|---------|
| **Technology** | Senescence-targeting therapeutics |
| **Funding** | $40M Series A (2024) -- led by Khosla Ventures and Ahren Innovation Capital |
| **Lead Candidate** | RLS-1496 (selective GPX4 modulator) |
| **Employees** | ~27 |

**Pipeline & Clinical Progress:**
- **RLS-1496** (selective GPX4 modulator):
  - **FDA IND cleared** for actinic keratosis (AK) -- **September 2025**.
  - **EMA-cleared trial** for psoriasis, dermatitis, and skin aging -- **May 2025**; first patient dosed.
  - Dual regulatory pathway (US FDA + European EMA) provides geographic diversification.

**Technology Platform:**
- Proprietary approach to selectively targeting senescent cells via GPX4 modulation.
- Focus on dermatological indications offers accessible clinical entry points with clear endpoints.

**Assessment:**
Rubedo has moved impressively fast from Series A to IND clearance. Their dermatology focus provides well-defined clinical endpoints and faster trial timelines. The dual US/EU regulatory strategy is prudent.

---

### 2.3 Dorian Therapeutics

| Field | Details |
|-------|---------|
| **Technology** | Senoblockers -- a novel class of therapeutics |
| **Mechanism** | Dual-function: block cellular senescence AND reactivate tissue regeneration |

**Technology & Focus:**
Dorian takes a fundamentally different approach from senolytics (which kill senescent cells). Their **senoblockers** prevent cells from entering senescence in the first place, while simultaneously reactivating regenerative capacity in affected tissues.

**Assessment:**
The senoblocker concept is scientifically appealing because it addresses senescence at the root rather than after the fact. If validated, this dual-function approach could have broad therapeutic utility. Clinical data will be needed to differentiate from senolytics.

---

### 2.4 Oisin Biotechnologies

| Field | Details |
|-------|---------|
| **Technology** | Gene therapy approach to senolytic therapy |
| **Approach** | Lipid nanoparticle delivery of senolytic gene constructs |

**Technology & Focus:**
Oisin uses a gene therapy approach to selectively eliminate senescent cells. Their platform delivers genetic constructs that activate apoptotic pathways specifically in cells expressing senescence markers (e.g., p16INK4a).

**Assessment:**
The gene therapy approach to senolytics offers the potential for high selectivity and potency. The key challenge is delivery efficiency and safety of repeated dosing.

---

## 3. Multi-Pipeline & Platform Companies

### 3.1 BioAge Labs

| Field | Details |
|-------|---------|
| **Focus** | Clinical-stage biopharmaceutical targeting the biology of aging for metabolic diseases |
| **Lead Candidate** | BGE-102 (NLRP3 inhibitor) |
| **IPO** | 2024 |

**Pipeline:**
- **BGE-102** (NLRP3 inhibitor):
  - Phase 1 SAD/MAD study planned for **2H 2025**.
  - Demonstrated weight loss as monotherapy and in combination with semaglutide in preclinical models.
  - NLRP3 inflammasome is a key driver of age-related inflammation ("inflammaging").
- **Novel oral picomolar-potency APJ agonists**: US patent granted **May 2025**. APJ receptor activation has been linked to cardioprotection and metabolic benefits.

**Partnerships:**
- **Novartis** (December 2024): Collaboration on aging and exercise physiology.
- **Eli Lilly ExploR&D** (January 2025): Partnership on metabolic aging.

**Assessment:**
BioAge's dual pharma partnerships (Novartis + Lilly) within two months validate their platform. The NLRP3 target connects aging biology to the massive metabolic disease market, particularly given the GLP-1 agonist revolution.

---

### 3.2 Cambrian Biopharma

| Field | Details |
|-------|---------|
| **Valuation** | $1.79 billion |
| **Funding** | $60M stealth exit (2021); $100M Series C |
| **Model** | Portfolio of aging-targeted therapeutic candidates |

**Pipeline:**
- Multiple candidates targeting different types of age-related damage:
  - **Obesity** indications
  - **Respiratory** diseases
  - **Oncology** programs
  - **Immunology** applications

**Assessment:**
Cambrian's portfolio approach spreads risk across multiple aging mechanisms and indications. The $1.79B valuation reflects investor confidence in the diversified strategy.

---

### 3.3 Insilico Medicine

| Field | Details |
|-------|---------|
| **Technology** | AI-powered drug discovery (Pharma.AI platform) |
| **Pipeline Status** | 20 preclinical candidates (2021-2024); 12-18 month turnaround; 100% success rate to IND |

**Pipeline (2024-2025):**

| Candidate | Target/Mechanism | Phase | Indication | Notes |
|-----------|-----------------|-------|------------|-------|
| ISM001-055 | TRAF2/Nck kinase inhibitor | Phase IIa (positive) | Idiopathic Pulmonary Fibrosis (IPF) | First AI-discovered drug to show efficacy |
| MEN2501 | Chromosomal instability | Phase I | Solid tumors | Novel mechanism |
| ISM3312 | Oral immunomodulatory | Phase I completed (2024) | Immunology | -- |
| ISM3091 | USP1 inhibitor | IND filed (2023) | Cancer | -- |
| ISM8969 | Brain-penetrant NLRP3 inhibitor | Preclinical | Neuroinflammation | Aging-relevant target |
| 2 oral GLP-1RAs | GLP-1 receptor | Nearing preclinical candidate | Metabolic disease | -- |
| 8 programs | Various | Preclinical | Cardiometabolic diseases | -- |

**Partnerships:**
- **Eli Lilly**: Deepened collaboration in 2025.
- **Sanofi**: Multi-target partnership.

**Track Record:**
- 20 preclinical candidates generated between 2021-2024.
- Average turnaround of 12-18 months from target to preclinical candidate.
- **100% IND success rate** -- every candidate submitted to regulators has been accepted.

**Assessment:**
Insilico's AI platform has demonstrated remarkable productivity and success rates. The positive Phase IIa data for ISM001-055 in IPF is a landmark for AI-driven drug discovery. Their expansion into aging-relevant targets (NLRP3, GLP-1) positions them at the intersection of AI and longevity.

---

### 3.4 Cellarity

| Field | Details |
|-------|---------|
| **Technology** | Cell-centric approach to drug discovery |
| **Approach** | AI-driven; focuses on cellular behavior rather than single molecular targets |

**Assessment:**
Cellarity's whole-cell approach is conceptually aligned with systems biology views of aging. Rather than targeting individual molecules, they model and modulate overall cellular states.

---

## 4. Gene Therapy for Aging

### 4.1 Rejuvenate Bio

| Field | Details |
|-------|---------|
| **Technology** | Gene therapy for aging |
| **Lead Program** | RJB-0402 |
| **Funding** | $4M grant from California Institute for Regenerative Medicine (CIRM, July 2024) |

**Technology & Focus:**
Rejuvenate Bio develops gene therapy approaches to address fundamental mechanisms of aging. Their work builds on research showing that combinatorial gene therapy (delivering multiple therapeutic genes) can reverse age-related decline in animal models.

**Assessment:**
The CIRM grant validates the scientific approach, though $4M is modest compared to peers. Gene therapy for aging faces delivery and safety challenges but could offer durable, single-dose interventions.

---

### 4.2 Shift Bioscience

| Field | Details |
|-------|---------|
| **Founded** | 2017, Cambridge, UK (Gurdon Institute) |
| **Founders** | Daniel Ives (CEO), Brendan Swain (CSO) |
| **Funding** | $16M seed (October 2024); $18M total raised |

**Technology Platform:**
- **AI-powered cell simulation platform**: Computationally models cellular aging and identifies intervention targets.
- **Biological aging clock**: Proprietary clock for measuring biological age and evaluating interventions.

**Pipeline:**
- **SB000**: Single-gene target for cellular rejuvenation, identified through their AI platform. Announced **June 2025**.

**Expansion:**
- Opening North American facilities (announced **February 2025**).

**Assessment:**
Shift's origin at the Gurdon Institute (home of Nobel Prize-winning reprogramming research) provides strong scientific pedigree. The AI-driven approach to identifying single-gene rejuvenation targets could yield highly druggable interventions.

---

## 5. Mitochondrial & Metabolic Targets

### 5.1 Amazentis / Timeline (Nestle)

| Field | Details |
|-------|---------|
| **Technology** | Urolithin A (branded as Mitopure) |
| **Parent/Affiliation** | Swiss health science company; Nestle connection |
| **R&D Investment** | $50M+ over 18+ years |
| **IP** | 80+ global patents |
| **Clinical Trials** | 25 registered human trials |

**Product:**
- **Mitopure** (Urolithin A): Commercially available supplement that enhances mitophagy (selective clearance of damaged mitochondria).

**Clinical Program:**
- **MitoImmune Study**: Results published in **Nature Aging (2025)** -- demonstrated immune system improvements with Urolithin A supplementation (expanded naive CD8+ T cells in 50 adults after 4 weeks at 1000mg/day).
- **CLARITY Study**: 650 participants; results expected **March 2026**. One of the largest controlled trials of a mitophagy enhancer, focused on brain health.

**Assessment:**
Amazentis has built one of the most robust clinical evidence bases for any nutraceutical/supplement in the aging space. Publication in Nature Aging and the scale of the CLARITY trial position Mitopure as a scientifically validated product.

---

## 6. Plasma-Based Therapies

### 6.1 Alkahest / Grifols

| Field | Details |
|-------|---------|
| **Founded** | 2014 |
| **Founder** | Tony Wyss-Coray (Stanford) |
| **Current Status** | Acquired by Grifols (global plasma therapeutics company) |

**Technology & Focus:**
- Plasma-based therapies for age-related diseases, built on parabiosis research showing that factors in young blood can rejuvenate aged tissues.
- Developing fractions of young donor plasma enriched in albumin and specific beneficial factors.
- Targeting neurodegeneration and cognitive decline.

**Scientific Foundation:**
- Tony Wyss-Coray's seminal work on heterochronic parabiosis demonstrated that young blood factors can reverse age-related cognitive decline in mice.

**Assessment:**
The acquisition by Grifols provides manufacturing scale and regulatory expertise for plasma-derived products. The scientific basis is compelling, though translating parabiosis findings to human therapeutics remains challenging.

---

## 7. AI-Driven Drug Discovery & Aging Clocks

### 7.1 Deep Longevity

| Field | Details |
|-------|---------|
| **Technology** | AI-based aging clocks, deep learning biomarker prediction |
| **Platform** | Aging.ai |

**Products & Technology:**
- **Deep Aging Clocks (DACs)**: Integrate multi-omics data (genomics, transcriptomics, proteomics, metabolomics) to produce comprehensive biological age estimates.
- **Aging.ai**: Online platform for biological age estimation from blood biomarkers.

**Assessment:**
Deep Longevity occupies a critical niche in providing aging measurement tools that can serve as endpoints for intervention trials. Multi-omic integration is the frontier of biological age estimation.

---

### 7.2 Gero AI

| Field | Details |
|-------|---------|
| **Technology** | GeroSense platform |
| **Approach** | AI-based biological age estimation from wearable and step counter data |

**Technology:**
- Uses passively collected wearable device data (step counts, activity patterns) to estimate biological age and mortality risk.
- Has **outperformed previous models** for biological age and mortality risk prediction.

**Assessment:**
Gero AI's wearable-based approach democratizes biological age assessment -- requiring no blood draws or clinic visits. If validated at scale, this could enable continuous, real-time biological age monitoring.

---

## 8. Diagnostics & Biomarker Companies

### 8.1 TruDiagnostic

| Field | Details |
|-------|---------|
| **Founded** | 2020 |
| **First Lab** | Opened April 2020 |
| **Products** | TruAge Complete ($499); TruAge PACE ($229) |

**Technology:**
- Most comprehensive commercial epigenetic testing available.
- Reports include:
  - **DunedinPACE** (third-generation pace-of-aging clock)
  - **OMICmAge** (multi-omic biological age)
  - **SYMPHONYAge** (composite aging metric)

**Assessment:**
TruDiagnostic offers the broadest panel of validated aging clocks in a single commercial test. Their inclusion of DunedinPACE -- the most clinically validated pace-of-aging metric -- is a key differentiator.

---

### 8.2 Elysium Health

| Field | Details |
|-------|---------|
| **Products** | Elysium Index ($299-$499); Basis supplement |
| **Index Test** | 10 areas of aging; 9 body system scores |
| **Supplement** | Basis (nicotinamide riboside + pterostilbene) |

**Assessment:**
Elysium bridges diagnostics and therapeutics by offering both testing and supplementation. The Index test provides a comprehensive view of biological aging across multiple body systems.

---

### 8.3 Tally Health

| Field | Details |
|-------|---------|
| **Founder** | David Sinclair (Harvard) |
| **Product** | TallyAge ($229) |
| **Technology** | Proprietary salivary DNA methylation algorithm |
| **Dataset** | 8,000+ person training dataset |
| **Turnaround** | Results in 4-6 weeks |

**Assessment:**
Tally Health's saliva-based approach lowers the barrier to testing (no blood draw needed). David Sinclair's involvement provides scientific credibility and public visibility, though his supplement advocacy has been controversial.

---

### 8.4 GlycanAge

| Field | Details |
|-------|---------|
| **Technology** | Glycan-based biological age testing |
| **Sample Type** | Finger prick home test |
| **Scientific Basis** | 200+ scientific publication citations |
| **Mechanism** | Measures inflammatory aging via glycan patterns on IgG antibodies |

**Assessment:**
GlycanAge offers a distinct modality from epigenetic clocks by measuring glycosylation patterns, which reflect immune system aging and chronic inflammation. The extensive publication record supports the scientific validity.

---

## 9. Veterinary Longevity

### 9.1 Loyal (Dog Aging)

| Field | Details |
|-------|---------|
| **Focus** | Dog lifespan extension |
| **Lead Drug** | LOY-002 (caloric restriction mimetic) |
| **Target Population** | Dogs 10+ years old, 14+ lb body weight |

**Regulatory Milestones:**
- **RXE (Reasonable Expectation of Effectiveness) acceptance**: February 2025
- **TAS (Technical Section) acceptance**: January 2026
- **XCA (eXperimental Conditional Approval)**: Anticipated from FDA by end of 2025

**Clinical Program:**
- **STAY Study**: Pivotal clinical trial
  - 1,000+ dogs enrolled
  - 70 clinical sites
  - First dog dosed: **December 2023**
  - **Largest veterinary clinical trial in history**

**Assessment:**
Loyal's regulatory progress is pioneering -- they are establishing the first-ever FDA approval pathway for a lifespan-extension drug (in any species). Success could create a template for human longevity therapeutics. The STAY study's scale demonstrates serious clinical rigor.

---

## 10. Summary Table

| Company | Founded | Funding | Core Technology | Stage | Key Milestone |
|---------|---------|---------|-----------------|-------|---------------|
| Altos Labs | 2022 | $3B | Cellular reprogramming | Early human testing | Safety testing Aug 2025 |
| Calico (Alphabet) | 2013 | Undisclosed (Alphabet) | Broad aging biology | Drug development | AbbVie $1.5B+ deal |
| Retro Biosciences | 2021 | $180M seed; ~$1B Series A | Reprogramming / autophagy / plasma | Pre-clinical/Phase 1 | Human trial Australia end 2025 |
| NewLimit | 2021 | $105M | Epigenetic reprogramming | Pre-clinical | -- |
| Turn Biotechnologies | -- | Undisclosed | ERA mRNA platform | IND-enabling | HanAll $300M deal; clinical 2026 |
| Life Biosciences | -- | Undisclosed | Partial reprogramming | Pre-clinical | Clinical trials early 2026 (eye) |
| Unity Biotechnology | -- | $55M Series C (2024) | Senolytics (BCL-xL) | Phase 2b | ASPIRE: 5.6 letters, NEJM Evidence |
| Rubedo Life Sciences | -- | $40M Series A (2024) | GPX4 modulation | Phase 1b/2a | FDA IND cleared Sept 2025 |
| Dorian Therapeutics | -- | Undisclosed | Senoblockers | Pre-clinical | Novel dual-function mechanism |
| Oisin Biotechnologies | -- | Undisclosed | Gene therapy senolytics | Pre-clinical | -- |
| BioAge Labs | -- | IPO 2024 | NLRP3 / APJ agonists | Phase 1 planned | Novartis + Lilly deals |
| Cambrian Biopharma | -- | $100M Series C | Multi-target portfolio | Multi-stage | $1.79B valuation |
| Insilico Medicine | -- | Undisclosed | AI drug discovery | Phase I-IIa | ISM001-055 positive Phase IIa |
| Shift Bioscience | 2017 | $18M | AI cell simulation | Pre-clinical | SB000 target June 2025 |
| Rejuvenate Bio | -- | $4M CIRM grant | Gene therapy | Pre-clinical | -- |
| Amazentis/Timeline | -- | $50M+ R&D | Urolithin A (Mitopure) | Commercial + Phase 2 | Nature Aging 2025 pub |
| Alkahest/Grifols | 2014 | Acquired by Grifols | Plasma fractions | Clinical | Grifols acquisition |
| Deep Longevity | -- | Undisclosed | AI aging clocks | Commercial | DACs, Aging.ai |
| Gero AI | -- | Undisclosed | Wearable-based aging | Commercial | GeroSense platform |
| TruDiagnostic | 2020 | Undisclosed | Epigenetic testing | Commercial | DunedinPACE, OMICmAge |
| Elysium Health | -- | Undisclosed | Epigenetic testing + supplements | Commercial | Index test + Basis |
| Tally Health | -- | Undisclosed | Salivary epigenetic testing | Commercial | TallyAge, 8K+ dataset |
| GlycanAge | -- | Undisclosed | Glycan-based testing | Commercial | 200+ publications |
| Loyal | -- | Undisclosed | Dog lifespan (CR mimetic) | Pivotal trial | STAY: largest vet trial ever |

---

## Key Trends & Observations

1. **Massive capital inflows**: The top companies (Altos $3B, Retro $1B+, Calico/Alphabet unlimited) command unprecedented funding for aging research.

2. **Convergence on reprogramming**: At least six companies (Altos, Retro, NewLimit, Turn Bio, Life Bio, Shift Bio) are pursuing some form of cellular or epigenetic reprogramming.

3. **Eye as first target**: Multiple companies (Unity, Life Bio, Turn Bio via HanAll) are targeting ocular indications as accessible first-in-human applications.

4. **AI integration**: Companies like Insilico, Shift Bio, Deep Longevity, and Gero AI are applying AI/ML across drug discovery and aging measurement.

5. **Pharma validation**: Major pharma partnerships (AbbVie-Calico, Novartis-BioAge, Lilly-BioAge, Lilly-Insilico, Sanofi-Insilico) signal mainstream acceptance of aging biology as a drug development paradigm.

6. **Diagnostic maturation**: Commercial biological age testing is now accessible at $229-$499, with multiple validated clock technologies available.

7. **2025-2026 inflection point**: Multiple companies are entering or planning human clinical trials in this window, marking the field's transition from discovery to translation.

---

*This document is a research compilation for informational purposes. Company details are based on publicly available information as of February 2025.*
